Posid 50mg Capsule

• Small cell lung cancer
• Testicular cancer

Most side effects of Posid 50mg Capsule do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Common side effects include:

• Anemia (low number of red blood cells)
• Decreased blood cells (red cells, white cells, and platelets)
• Decreased white blood cell count
• Diarrhea
• Hair loss
• Liver damage
• Low blood platelets
• Nausea
• Rash
• Stomatitis (Inflammation of the mouth)
• Vomiting

• The dosage and duration of the Posid 50mg Capsule are decided by the doctor based on the severity of the infection and other health factors. Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history.
• If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.​​
  

• Posid 50mg Capsule is an anticancer medicine with Etoposide as an active ingredient. It belongs to the class of drug known as topoisomerase II inhibitors. It works by blocking the activity of an enzyme known as topoisomerase II responsible for DNA multiplication in cancer cells.
• Thereby, it slows down the growth & multiplication of cancer cells and eventually kills them.​​
  

• Perez-Soler, R., Glisson, B. S., Lee, J. S., Fossella, F. V., Murphy, W. K., Shin, D. M., & Hong, W. K. (1996). Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Journal of clinical oncology, 14(10), 2785-2790.
• Dearnaley, D. P., Horwich, A., A'Hern, R., Nicholls, J., Jay, G., Hendry, W. F., & Peckham, M. J. (1991). Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. European Journal of Cancer and Clinical Oncology, 27(6), 684-691.
• Varini, M., & Cavalli, F. (1982). Etoposide for therapy-resistant testicular tumors. Cancer Treatment Reviews, 9, 73-78.
• Henwood, J. M., & Brogden, R. N. (1990). Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs, 39(3), 438-490.
• Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaı̂tre, F., ... & European Lung Cancer Working Party (ELCWP. (2000). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung cancer, 30(1), 23-36.
• Loehrer Sr, P. J. (1991). Etoposide therapy for testicular cancer. Cancer, 67(S1), 220-224.